Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 3:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,852 matching trials from the live ClinicalTrials.gov search.
Conditions
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Interventions
REL-1017, Placebo
Drug
Lead sponsor
Relmada Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Little Rock, Arkansas • Garden Grove, California • San Diego, California + 7 more
Conditions
Depressive Disorder, Major
Interventions
Rapastinel
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
128
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 104 more
Conditions
Dyspareunia
Interventions
Prasterone
Drug
Lead sponsor
San Diego Sexual Medicine
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Diego, California
Conditions
Bipolar Disorder
Interventions
Quetiapine
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Postpartum Depression
Interventions
SAGE-547
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Major Depressive Disorder, Back Pain, Aged
Interventions
Duloxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
TOURETTE SYNDROME
Interventions
SD-809
Drug
Lead sponsor
Auspex Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Houston, Texas
Completed No phase listed Observational Accepts healthy volunteers

Dopamine Neurotransmission in Major Depression

NCT01659814
Conditions
Major Depressive Disorder, Anhedonia
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Conditions
Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Maryland Oncology Hematology, PA
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rockville, Maryland
Conditions
Major Depressive Disorder
Interventions
"Engage & Connect" Psychotherapy, Symptom Review and Psychoeducation (SRP)
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Completed Phase 3 Interventional Results available

A Long-Term Safety Study of ALKS 5461

NCT02141399
Conditions
Major Depressive Disorder
Interventions
ALKS 5461
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
123
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 105 more
Conditions
Traumatic Brain Injury, Major Depressive Disorder, Bipolar Disorder, Schizophrenia, Attention Deficit Hyperactivity Disorder, Borderline Personality Disorder, Substance Use Disorders
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
40
States / cities
Dothan, Alabama • Phoenix, Arizona • Imperial, California + 34 more
Conditions
Schizophrenia, Schizo-affective Disorder
Interventions
Illness Management and Recovery, Problem Solving
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Completed Not applicable Interventional Results available

rTMS for PTSD Comorbid With Major Depressive Disorder

NCT02273063
Conditions
Posttraumatic Stress Disorder, Major Depressive Disorder, Transcranial Magnetic Stimulation, Repetitive
Interventions
Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Providence, Rhode Island
Completed Phase 3 Interventional Results available

Opiate Suicide Study in Patients With Major Depression

NCT04116528
Conditions
Major Depressive Disorder
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Stanford, California
Conditions
Major Depression
Interventions
Escitalopram
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more
Conditions
Major Depressive Disorder, Persistent Depressive Disorder, Posttraumatic Stress Disorder, Panic Disorder, Social Phobia, Specific Phobia, Generalized Anxiety Disorder, Obsessive Compulsive Disorder
Interventions
Transdiagnostic Behavior Therapy, Behavioral Activation Therapy
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Schizophrenia, Bipolar Disorder, Depressive Disorder, Major, Stress Disorder, Post-Traumatic
Interventions
Social Cognition and Interaction Training-Work Edition (SCIT-WE)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Depressive Disorder, Major
Interventions
JNJ-89495120, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more
Not yet recruiting Not applicable Interventional

Deaf CBT-TS to Reduce Suicide Risk

NCT07279363
Conditions
Depression - Major Depressive Disorder, Anxiety, PTSD - Post Traumatic Stress Disorder, Insomnia, Alcohol Use Disorder (AUD), Suicide Ideation
Interventions
Deaf CBT-TS
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, New York
Conditions
Major Depression
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Garden Grove, California • Orlando, Florida • Atlanta, Georgia + 5 more
Conditions
Major Depressive Disorder
Interventions
Placebo, RO4995819
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
43
States / cities
Phoenix, Arizona • Oakland, California • Redlands, California + 37 more